The European Commission approved Alnylam's AMVUTTRA, and Dr. Pushkal Garg was appointed to accelerate R&D efforts.
1 report, 0 independent
Updated Jun 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Commission approved Alnylam's AMVUTTRA, and Dr. Pushkal Garg was appointed to accelerate R&D efforts.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
Coverage
Newest first; wire copies grouped- Unknown outlet